Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0368 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0368 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0368 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0368 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0368 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0186 | 0.0151 | 0.0151 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0368 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0368 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0368 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0368 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0228 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0368 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0368 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0368 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0368 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0183 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0368 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0368 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0368 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0368 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0368 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0368 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0228 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0183 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0368 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0327 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0368 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0327 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0368 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Aspirin formed (ADMET) | = 8 % | Percentage of aspirin formed during hydrolysis of the compound in 10% human plasma at pH 7.4 at 37 degrees celsius | ChEMBL. | 2918521 |
Aspirin formed (ADMET) | = 8 % | Percentage of aspirin formed during hydrolysis of the compound in 10% human plasma at pH 7.4 at 37 degrees celsius | ChEMBL. | 2918521 |
K obs (ADMET) | = 834 min-1 | Observed pseudo-first order rate constant | ChEMBL. | 2918521 |
K1 (ADMET) | = 67 min-1 | Observed first order rate constant | ChEMBL. | 2918521 |
K2 (ADMET) | = 767 min-1 | Observed second order rate constant | ChEMBL. | 2918521 |
Km (ADMET) | = 0.000087 M | Michaelis-Menten constant(Km) of the compound for hydrolysis in 10% human plasma(pH 7.4) at 37 degrees celsius | ChEMBL. | 2918521 |
Km (ADMET) | = 870000 M | Michaelis-Menten constant(Km) of the compound for hydrolysis in 10% human plasma(pH 7.4) at 37 degrees celsius | ChEMBL. | 2918521 |
logP (ADMET) | = 2.09 | Partition coefficient (logP) | ChEMBL. | 2918521 |
Ratio (ADMET) | = 0.083 min-1 | Ratio of Vmax to Km values of the compound | ChEMBL. | 2918521 |
S | = 0.72 mg ml-1 | Solubility (21 degrees C) | ChEMBL. | 2918521 |
T1/2 (ADMET) | = 8.3 min | t1/2 in 10% human plasma | ChEMBL. | 2918521 |
T1/2 (ADMET) | = 8.300000000000004 min | t1/2 in 10% human plasma | ChEMBL. | 2918521 |
Vmax (ADMET) | = 72000 M min-1 | Vmax of the compound of the compound for hydrolysis in 10% human plasma(pH 7.4) at 37 degrees celsius | ChEMBL. | 2918521 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.